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Background: Quantification and normalization of RT-qPCR data critically depends on the expression of so called
reference genes. Our goal was to develop a strategy for the selection of reference genes that utilizes microarray
data analysis and combines known approaches for gene stability evaluation and to select a set of appropriate
reference genes for research and clinical analysis of breast samples with different receptor and cancer status using
this strategy.
Methods: A preliminary search of reference genes was based on high-throughput analysis of microarray datasets.
The final selection and validation of the candidate genes were based on the RT-qPCR data analysis using several
known methods for expression stability evaluation: comparative ΔCt method, geNorm, NormFinder and Haller
equivalence test.
Results: A set of five reference genes was identified: ACTB, RPS23, HUWE1, EEF1A1 and SF3A1. The initial selection
was based on the analysis of publically available well-annotated microarray datasets containing different breast
cancers and normal breast epithelium from breast cancer patients and epithelium from cancer-free patients. The
final selection and validation were performed using RT-qPCR data from 39 breast cancer biopsy samples. Three
genes from the final set were identified by the means of microarray analysis and were novel in the context of
breast cancer assay. We showed that the selected set of reference genes is more stable in comparison not only
with individual genes, but also with a system of reference genes used in commercial OncotypeDX test.
Conclusion: A selection of reference genes for RT-qPCR can be efficiently performed by combining a preliminary
search based on the high-throughput analysis of microarray datasets and final selection and validation based on
the analysis of RT-qPCR data with a simultaneous examination of different expression stability measures. The
identified set of reference genes proved to be less variable and thus potentially more efficient for research and
clinical analysis of breast samples comparing to individual genes and the set of reference genes used in
OncotypeDX assay.
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Gene-expression analysis is ubiquitously used both in
life sciences and in medical research [1-3]. Microarray
and reverse transcription quantitative real-time polymer-
ase chain reaction (RT-qPCR) analyses are commonly
used to measure transcript abundance. Microarrays
allow the massive parallel analysis of thousands of genes
but still require significant time and financial expenses.
RT-qPCR is used as a conventional routine method for
expression profiling of a moderate number of genes and
is highly suitable when only a small amount of sample is
available [1,4]. High throughput thermal cyclers and
PCR platforms help to overcome the limitation of
RT-qPCR and to perform simultaneous expression ana-
lysis of tens and hundreds of genes for one or more
samples depending on the platform [1].
In research practice these two technologies are able to
solve a broad spectrum of questions supplementing each
other. In clinical diagnostics RT-qPCR is still more
popular with the advantage of speed and a relatively low
cost [5].
Based on a totally different readout strategy, RT-qPCR
has become the standard method for validation of
microarray data. However, the application of RT-qPCR
requires an appropriate normalization to obtain accurate
and reliable quantification of gene expression levels. The
purpose of normalization is to remove experimentally
induced errors that can be introduced at a number of
stages throughout the procedure (variability in sample
acquisition and RNA extraction protocols, different re-
verse transcription reactions and PCR efficiencies) and
to reveal the true biological changes in expression
[4,6-8]. Lack of appropriate normalization can lead to
misinterpretation of a target gene expression profile.
This is especially pronounced when the samples come
from different individuals, different tissues, different
time courses, different environmental conditions, etc.
To date, the reference gene concept is a gold standard
used for normalization [1]. According to this concept
reference genes are endogenous controls whose expres-
sion remains stable across all sources of variation during
the experimental workflow. Results of RT-qPCR studies
that use improper reference genes (e.g. genes that are
not constitutively expressed) can be significantly differ-
ent from results obtained with proper reference genes
[7,9,10]. So far, as ideal reference genes do not exist, it is
essential to select appropriate reference genes for accur-
ate normalization of the RT-qPCR results for each
experimental condition. It is worth noting that the ex-
pression levels of many commonly used reference genes
such as GAPDH, ACTB, RPS18, UBC, B2M, and HPRT1
have been reported to vary considerably in multiple tis-
sues and cells [4,7,9,11-15]. However, in the absence of a
better choice, the majority of researchers continue touse these genes, sometimes even without preliminary
validation [9,13,16]. Thus for many studies there is a ne-
cessity to identify other candidate reference genes. One
of possible ways is RT-qPCR screening of all 535 tran-
scripts involved in maintaining cellular function by
RT-qPCR [11,15]. Another way in our genomic era is to
use the wealth of accumulated available data obtained by
high-throughput microarray and sequencing technolo-
gies. This idea is getting more and more popular and
was used in some recent studies of plants [17-19], dia-
toms [20], mammals [21,22] and human [23-27]. Certain
attempts were also made to assess the stability character-
istics of transcripts in different tissue types and cells
of several species in different physiological states
[14,28,29]. However, no genes were identified as gener-
ally stably expressed. Thus it is still a problem to reveal
genes that are stably expressed in a given biological con-
text, and the analysis of well-annotated microarray data
may be very helpful to solve this problem. This approach
promises to be particularly fruitful for heterogenic sam-
ples like biopsies which may contain different cell types
in different ratios that can vary widely between samples.
In this study, we identified a set of genes that can be
used as a reference simultaneously for analysis of breast
cancer samples with an unknown hormone receptor sta-
tus and different cancer status. To achieve this goal we
analyzed four available well-annotated Affymetrix Hu-
man Genome U133A array datasets containing different
breast cancers and normal breast epithelium from breast
cancer and cancer-free patients. Then we validated iden-
tified candidate reference genes by RT-qPCR on 39 fresh
breast cancer biopsies and compared expression stability
of these genes and commonly used control genes includ-
ing ACTB, GAPDH, RPLP0, GUSB and TFRC that form
a set of reference genes in a commercial Oncotype DX
Breast Cancer diagnostic test [2].
In order to select an optimal set of reference genes we
developed a new strategy that utilizes the advantages of
the most widely used algorithms for gene stability
evaluation: comparative ΔCt method [8], geNorm [12],
NormFinder [1,30] and Haller equivalence test [31].
Each of these popular methods for gene stability evalu-
ation has its own advantages and pitfalls, and the devel-
oped strategy allows scientists to avoid weighing all the
pros and cons of individual methods each time, but in-
stead to combine all these methods. We showed that
novel candidate reference genes identified by our micro-
array search have expression stability comparable to or
even higher than the stability of commonly used refer-
ence genes. We also demonstrated that the selected set
of 5 reference genes is more stable than the set of 5
reference genes used in Oncotype DX Breast Cancer
diagnostic test. The RT-qPCR data used for the valid-
ation study was obtained in compliance with the global
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lines [32], see Additional file 1.
Methods
Large-scale selection of an extended list of candidate
reference genes using microarray data
Four GEO Series [33,34] of Affymetrix Human Genome
U133A array data were taken: GSE17705 (title: “Endocrine
Sensitivity Index Validation Dataset”, 298 samples, [35]),
GSE10780 (title: “Proliferative genes dominate malignancy-
risk gene signature in histologically-normal breast tissue”,
185 samples, [36]), GSE20711 (title: “Epigenetic portraits of
human breast cancers (expression data)”, 90 samples, [37]),
GSE20437 (title: “Histologically normal epithelium from
breast cancer patients and cancer-free prophylactic mastec-
tomy patients”, 42 samples, [38]).
For each data series raw microarray data were processed
using Bioconductor [39] xps package [40] implementation
of RMA [41]. For each probeset a variability characteristic
was computed as a ratio of 95- and 5-percentiles of log-
transformed expression levels, and an ascending ordering
of probesets was performed according to this variability
characteristic. After these steps four lists of probesets were
obtained (each corresponding to one data series). Genes
corresponding to probesets that belong to top-500 for all
four lists were included into the extended list of candidate
reference genes.
The variability characteristic used for stability ranking is
methodologically close to the interquartile range, but con-
trols expression variation for 90 percent of samples in a
dataset instead of 50 percent. Unlike mean deviation and
standard deviation that are commonly used for expression
stability comparison [14,15,24] the ratio of quantiles is ab-
solutely stable with respect to data outliers.
For genes with stable expression the stability ranking
based on the ratio of 95- and 5-percentiles of log-
transformed expression levels is similar to ranking based
on a relative width of expression range in a logarithmic
scale: if 5-percintile p5 of log-transformed expression level
equals m(1-w), and 95-percintile p95 equals m(1 + w), and
0 ≤ w<< 1 then
p95
p5
¼ m 1þ wð Þ
m 1−wð Þ ¼ 1þ wð Þ 1þ wþ w
2 þ… 




The top-500 lists of most stable probesets for four
datasets used for the generation of an extended list of
candidate genes contained 347–410 unique gene sym-
bols. However, pairwise intersection of top-500 lists cor-
responding to two datasets (GSE17705 – ER-positive
breast cancer patients [35]; GSE20711 – breast cancer
patients [37]) contained only 48 unique gene symbols,and interception of top-500 lists corresponding to three
datasets (a small dataset GSE20437 – histologically nor-
mal epithelium from breast cancer patients and cancer-
free prophylactic mastectomy patients [38] – added)
contained 27 unique gene symbols. Hence, our extended
list of candidate reference genes – it contained 25
unique gene symbols – was formed based mainly on
three datasets out of four, and the forth dataset
(GSE10780 – a larger set of histologically-normal breast
tissues from breast carcinoma patients [36]) only vali-
dated our selection.
Patients
For validation of reference genes, samples from 39 pa-
tients (mean age 60.5 years; range 35–87 years) were an-
alyzed. Patients were treated for breast cancer at the
Gertsen Moscow Research Institute of Oncology or the
Moscow State Oncology Medical Center, Russia, in
2012. Patient selection was based only on the availability
of tumor tissue. All patients gave written informed
consent to access their tissues and review their medical
records in accordance with the principles of the
Declaration of Helsinki. All patients were treated by
mastectomy. Patients did not receive neoadjuvant
chemotherapy.
Histologically, 32 tumors were diagnosed as ductal car-
cinomas, 1 was a mucus-producing adenocarcinoma,
and 6 were of other histological types. TMN classifica-
tion of all tumors is presented in Additional file 2.
Twenty five tumors (64%) were estrogen-receptor (ER)
positive, and 14 cases (36%) were ER-negative. Progester-
one receptors (PR) were detectable in 24 cases (61.5%),
whereas 15 tumors (38.5%) were PR-negative. Detailed
information about tumor receptor status is provided in
Additional file 2. All tumor samples were placed in ap-
propriate volume of RNAlater RNA stabilization reagent
(Qiagen, Germany) within 30 min after mastectomy and
incubated at 4°C at least overnight but no more than 3
days. If total RNA was not isolated from a tissue sample
after 3 day incubation, the sample was frozen at −80°C.
RNA extraction and quality control
Tumor samples stabilized in RNAlater reagent were
crushed in liquid nitrogen. QIAzol lysis reagent (Qiagen,
Germany) was added and the homogenate was
centrifuged through a QIAshredder column (Qiagen,
Germany). Total RNA was extracted from the eluate by
the miRNeasy mini kit (Qiagen, Germany) according to
the manufacturer’s instructions. Genomic DNA contam-
ination was removed by performing DNaseI digestion
on the RNA binding column for 15 min. Total RNA
was eluted in 50 μl of RNase-free H2O and stored at
−80°C. RNA yield and purity was assessed spectrophoto-
metrically by measuring OD260 and OD260/280 ratio
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1000 (NanoDrop Technologies, USA). For all samples
OD260/280 ratio was between 2.0 and 2.2.
RNA integrity was determined using the Experion
Automated Electrophoresis Station with the standard-
sensitivity RNA analysis kit according to the manufac-
turer’s instructions (Bio-Rad, USA). Values of RNA
quality indicator (RQI) generated by Experion system’s
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A gene list used for validation is presented in Table 1.
Primer pairs and probes were designed using Primer3
software [42] according to the recommendations de-
scribed in [43], and their specificity was determined with
Primer-blast program [44]. All sequences were tested for
potential secondary structure and dimerization forma-
tion using OligoAnalyzer 3.1 program [45]. Primer spe-
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in Table 2 (see details in Additional file 3). Oligonucleo-
tides were synthesized by Syntol (Russia).
The amplification efficiency of each set of primer pair
and probe was determined by plotting the Ct values
obtained for 7 serial dilutions of cDNA (1:25, 1:100,
1:250, 1:500, 1:1000, 1:2500, and 1:5000). For this aim
cDNA was synthesized by reverse transcription of the
RNA pool which was prepared by mixing of an equal
amount of total RNA isolated from five random tumor
samples from the biopsy collection. The corresponding
RT-qPCR primer efficiencies (E) were calculated
according to the equation E = 10(−1/slope). Each reaction
was performed in triplicates. All PCR-mixes were
pipetted by the automated pipetting system epMotion
5075 (Eppendorf, Germany).
PCR efficiencies for all candidate reference genes were
higher than 1.83 and lower than 2.1 (Table 2, see
Additional files 4 and 5), except for TPT1 (1.76). The
amplicon sizes for all primer pairs are presented in
Table 2.
cDNA synthesis and quantitative RT-qPCR
RNA samples were reverse transcribed to cDNA with
the Reverse Transcription reaction mix using random
hexamer primer according to the manufacturer’s instruc-
tion (Syntol, Russia). Initially 2 μg of total RNA was in-
cubated at 65°C for 5 min followed by an incubation
with 10 μl 2.5× reaction mix, 1 μl of 15 OD/μl random
hexamer, 1 μl of 50U/ μl MMLV reverse transcriptase,
1 μl of 5U/ μl RNase inhibitor and nuclease-free water
in final volume 25 μl for 1 hour at 37°C and 5 min at
95°C. First strand cDNA samples were stored at −20°C.
To measure the transcript levels of selected candidate
genes by RT-qPCR, a 2.5× PCR reaction mix for qPCR
(Syntol, Russia) was applied and analysis was performed
on a 96-well DT-prime detection system (DNA-Technol-
ogy, Russia). Each reaction was performed in triplicates
in a reaction volume of 25 μl in high-profile 96-well
unskirted PCR plates (BioRad, USA). All reactions
contained 1 μl of cDNA diluted in 10 times, 10 μl of
2.5× Master Mix containing 6.25 mM MgCl2, 2.5 μl of
25 mM MgCl2 (till final concentration in a reaction mix
5 mM), 0.6 μl of 10 μM of each primers, 0.6 μl of 10 μM
of a probe and 9.7 μl of DNase/RNase-free water. The
PCR program consists of an initial 10 min template de-
naturation step at 94°C for enzyme activation, followed
by 50 cycles of 94°C for 20 sec, 64°C for 10 sec, and 72°C
for 15 sec. Nontemplate controls were also performed
in triplicate for each gene set of primer pair and probe.
Sets for all 18 candidate genes were analyzed in the same
run. Each run was repeated three times. All PCR-mixes
were pipetted by the automated pipetting system
epMotion 5075 (Eppendorf, Germany). To verify thepresence of genomic DNA contamination in the isolated
total RNA, RT-qPCR were performed on equivalent
amounts of total RNA without reverse transcription
(as template) for each tumor sample.
Baseline and threshold values were automatically de-
termined for all reactions in the plate using RealTime
PCR v.7.3 software (DNA-Technology, Russia).
All RT-qPCR experiment data comply with the
Minimum Information for Publication of Quantitative
Real-Time PCR Experiments (MIQE) guidelines [32].
The MIQE checklist is presented in Supplementary In-
formation (see Additional file 1).
Analysis of gene expression stability by RT-qPCR
To analyze the stability of the candidate reference genes,
four different methods were used [9]: comparative ΔCt
method, geNorm, NormFinder and Haller equivalence
test. Briefly, the geNorm tool is based on the principle
that the expression ratio of two ideal reference genes
should be constant in samples from different experimen-
tal conditions or cell types [12]. The expression stability
value (MgeNorm) of a gene is defined as the standard de-
viation of the log-transformed expression ratio for the
particular gene relative to all other genes under investi-
gation in a panel of cDNA samples. Lower values of
MgeNorm correspond to higher gene expression stability.
Because a freely available geNorm program does not
allow the data to be processed efficiently if the RT-qPCR
for each cDNA is repeated several times, we performed
the geNorm analysis of our RT-qPCR data manually as
described in [9].
The comparative ΔCt method compares a Ct ratio of
“pairs of genes” within each sample and assigns a relative
variation value MΔCt to each gene. Higher values of rela-
tive variation MΔCt correspond to lower gene expression
stability.
NormFinder is a freely available program [46] which cal-
culates the stability index using analysis of variance
(ANOVA) on log-transformed expression values [1,30].
The NormFinder algorithm estimates overall gene expres-
sion variation MNormFinder as well as the variation between
subgroups, such as ER-positive and ER-negative breast
cancer tissue samples. Higher values of MNormFinder cor-
respond to higher gene expression variability.
Haller equivalence test gives for each pair of samples





difference in samples k, l [31]. An integral measure of
gene variability in Haller equivalence test approach




k≠l with a confidence level α set to 0.05.
Similarly to the other approaches considered in our
study, the higher MHaller value corresponds to higher
gene expression variability. The analysis of gene
Table 2 Description of primers and probes for validated candidate reference genes
Gene name Sequence of primers and probes* Amplicon size (bp) E
HCFC1 f-CCACATCGACTACACCACCAA 212 1.90
r-CAGCTTCCTCTCACTGACCATC
pr-(FAM)-CGCCATCA(T-BHQ1)CTTCCGCATCGCC-(P)
TPT1 f-ATCAGCCACGATGAGATGTTC 132 1.76
r-ATTTCCACCAATGAGCGAGTC
pr-(FAM)-CGGACGGG(T-BHQ1)TGTGCCTGGAGGT-(P)
RPL37A f-AAGTCGGGATCGTCGGTAAA 112 1.97
r-TTGCCACAGAAAGAGCAAGT
pr-(FAM)-TTGAAA(T-BHQ1)CAGCCAGCACGCCAAGT-(P)
PTMA f-ACCACCCAACCCAAACCA 238 1.85
r-TGGTCACACCACAAGTAAAGT
pr-(FAM)-TCGGATGACCAAACCAGCC(T-BHQ1)TCGG-(P)
RPL23A f-CTGGAAGAGGCTGTGTATGAA 120 1.96
r-TAGTAGATGGGTGTGTGAGGAC
pr-(FAM)-AGGGGAG(T-BHQ1)GTGGATTGGCTGGC-(P)
TBP f-TTCGGAGAGTTCTGGGATTGTA 227 1.83
r-TGGACTGTTCTTCACTCTTGGC
pr-(FAM)-CCGTGGTTCG(T-BHQ1)GGCTCTCTTATCCTCAT-(P)
GUSB f-CTCATTTGGAATTTTGCCGATT 81 1.87
r-CCGAGTGAAGATCCCCTTTTTA
pr-(FAM)-TGAACAG(T-BHQ1)CACCGACGAGAGTGCTGG-(P)
SF3A1 f-AAGGGTCCAGTGTCCATCAAAGT 224 1.88
r-GCCATGTTGTAGTAAGCCAGTGAG
pr-(FAM)-ACCAGGTC(T-BHQ1)CTGTCATTAAGGTGAAG-(P)
MRPL19 f-TGTTTGCGGTTGTTAGTTCAC 239 1.87
r-ACATTTCTGCTTGCCCTTCC
pr-(FAM)-CATTGCC(T-BHQ1)ACTGCTTACGATGAGTGC-(P)
ACTB f-CTGGAACGGTGAAGGTGACA 140 1.87
r-AAGGGACTTCCTGTAACAACGCA
pr-(FAM)-TGGAGCGAGCA(T-BHQ1)CCCCCAAAGT-(P)
GAPDH f-GAAGGTGAAGGTCGGAGTC 226 1.99
r-GAAGATGGTGATGGGATTTC
pr-(FAM)-CAAGCTTCCCG(T- BHQ1)TCTCAGCC-(P)
RPLP0 f-CTGATCCATCTGCCTTTGTG 116 1.89
r-GTCCGACTCCTCCGACTCTT
pr-(FAM)-AGCCCCAGC(T-BHQ1)AAGGTTGAAGCCA-(P)
TFRC f-AAAGGAAATGGGCCTGAGTTTA 92 1.96
r-CATTCCCGAAATCTGTTGTTAG
pr-(FAM)-TGGCTGTATTC(T-BHQ1)GCTCGTGGAGA-(P)
PSMC4 f-AGCTCTACAAGCAGATCG 80 1.95
r-CAACATGGTCTTCCCACA
pr-(FAM)-AGGCGTCCTCATG(T-BHQ1)ATGGCCCACCT-(P)
HUWE1 f- CAGAGTTGGACAGAGTGAAA 137 2.10
r- TACACAGAGAGAGGAGGACA
pr-(FAM)-TCGTTCCATCTCCG(T-BHQ1)AAACCAG-(P)
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Table 2 Description of primers and probes for validated candidate reference genes (Continued)
EEF1A1 f-TGAAAACTACCCCTAAAAGCCA 208 1.91
r- TATCCAAGACCCAGGCATACT
pr- (FAM)-TAGATTCGGGCAAG(T-BHQ1)CCACCA-(P)
RPS23 f- CGGTGCTTCTCTCTTTCGCT 110 2.00
r- ATGCCACTTCTGGTCTCGT
pr- (FAM)-AGTGTCG(T-BHQ1)GGACTTCGTACTGC-(P)
RPL39 f- TTATGCTGTCTGAAGGTCACGA 120 1.85
r- AATCCAGCCAACCAACGTG
pr- (FAM)-TGGAGATT(T-BHQ1)CGACGTGTTTTCCTCTC-(P)
*All oligodeoxynucleotide sequences are given in 5’→ 3’ direction, f – a forward primer, r – a reverse primer, pr – a probe.
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scribed in details in [9].
Gene expression levels were estimated using a stand-
ard exponential model A = I/ECt, where A is an expres-
sion level, I is a threshold value, Ct is a number of cycle
corresponding to the threshold value, and E is a qPCR
efficiency for a gene.
Data generation for “quasi-genes”
In order to compare the stability of a set of reference
genes with the stability of individual genes using
standard methods that were used for the stability evalu-
ation of genes (comparative ΔCt method, geNorm,
NormFinder, Haller equivalence test) we implemented a
simple procedure that generates data for a “quasi-gene”
that can be associated with a set of reference genes.
An expression level, assigned to a “quasi-gene” by this
procedure, was equal to a normalization factor defined
by the set of genes, or, in other words, to the geometric
mean of expression levels for genes that belong to the
set: ~A ¼ ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ∏ni¼1Ain
p
,
In order to find an appropriate Ct-value ~C , required by
some methods for stability evaluation, we used a standard
exponential model I =AECt, where A is an expression level,
E is a gene efficiency, I is a threshold, Ct is threshold cycle.
We also accepted as a fact that all Ct-values for a fixed sam-
ple correspond to the same threshold ~I , and set an efficiency
for a “quasi-gene” to the geometric mean of efficiency values
of genes in the set ~E ¼ ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ∏ni¼1Ein
p Þ . Due to the exponential
model assumptions, log~E~I ¼ log~E ~A þ ~C log~E ~E ¼ log~E ~Aþ
~C , so Ct-value, assigned to by the procedure to a “quasi-








∑ni¼1 logThe RT-qPCR data contained 3 replicates for every
gene and 3 replicates for every sample, and hence, there
were nine Ct-values for each gene-sample pair. Taking
the respective Ct-values of this 3x3 matrix for each gene
of a system we got the corresponding matrix of
Ct-values for a “quasi-gene”.
Results
The strategy for the selection of reference genes that
was used in this study consists of the following stages:
the large-scale screening of an extended list of candidate
reference genes based on microarray data series, the
selection of a candidate gene set for validation by
RT-qPCR, and the determination of the final set of refer-
ence genes.
Large-scale selection of an extended list of candidate
reference genes based on microarray data
The large-scale selection of the extended list of candi-
date reference genes was performed by a selection of
genes that are present in sub-lists of most stable genes
in all four analyzed microarray data sets (see the details
in the Methods). Note that this approach allows a com-
bining of microarray studies that utilize different micro-
array technologies. The total number of such genes was
25 (Table 3). Sixty percent of these genes (15 genes)
were present in the list of maintenance genes expressed
across eleven human adult and fetal tissues [11], and 9
percent (3 genes) were also present in the list of 47 tran-
scripts expressed at the same level across eleven human
adult and fetal tissues [11]. The extended list of candi-
dates included eight RPL and eight RPS genes. These re-






Table 3 An extended list of candidate reference genes
Gene symbol L11* L11_eq** L19***
ACTG1 + – +
EEF1A1 + + +
HCFC1 – – –
HNRNPA1 – – –
HUWE1 – – –
NACAP1 – – –
PKD2L1 – – –
PTMA + – +
RPL10 + – –
RPL22 – – –
RPL23A – – –
RPL37A + + +
RPL39 + – +
RPL41 + + +
RPL7 + – +
RPL9 + – +
RPS10 + – +
RPS15A – – –
RPS16 + – +
RPS18 + – +
RPS20 + – –
RPS23 – – +
RPS3A – – +
RPS4X + – –
TPT1 + – +
*L11: presence of a gene in the list of maintenance genes expressed in eleven
human adult and fetal tissues [11].
**L11_eq: presence of a gene in the list of 47 transcripts expressed at the
same level in eleven human adult and fetal tissues [11].
***L19: presence of a gene in the list of 451 housekeeping genes from 19
normal human tissue types [15].
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used for normalization of RT-qPCR data, were not in-
cluded into the resulting extended list of candidate
genes. The GAPDH gene did not belong to any list of
top-500 stable probesets, while gene ACTB (as well as
UBC) belonged to three lists of top-500 stable probesets,
but was not present in top-500 list corresponding to a
dataset of histologically normal epithelium from breast
cancer patients and cancer-free prophylactic mastectomy
patients (GSE20437). It is also worth noting that ACTB
and UBC (in contrast with, e.g., GUSB) had high
intergroup difference in expression level for samples
from cancer and cancer-free patients. However, the
intragroup variation was low for each of the groups.
Hence, the assessment of the expression level of these
genes can be potentially used for the estimation of a
tumor/normal epithelium ratio in a biopsy sample. Anability of housekeeping genes to define different bio-
logical states was also reported in [15].
Selection of a gene set for the experimental validation
and RT-qPCR validation
The selection of a gene set for validation from the pre-
liminary extended list was performed by an identification
of genes with the highest stability values in the majority
of the analyzed microarray data series, but the following
additional limitation was imposed: a simultaneous selec-
tion of genes with known interactions, as well as a selec-
tion of genes with similar biological functions should be
minimized. Informally, this limitation increases the inde-
pendence of genes in the selected set.
Nine genes from the extended list of candidate refer-
ence genes (TPT1, HCFC1, PTMA, RPL23A, RPL37A,
RPL39, RPS23, HUWE1, EEF1A1) were selected for the
experimental validation of the expression stability and
comparison with other genes traditionally used as refer-
ence genes in RT-qPCR studies of breast tissue (ACTB,
GAPDH, RPLP0, GUSB, TFRC, SF3A1, MRPL19, PSMC4,
TBP [2,23,27,47,48]) (Table 1). As no unique criterion ex-
ists for the comparison of gene expression stability, we
combined four different approaches: comparative ΔCt
method [8], geNorm [12], NormFinder [1,30], and Haller
equivalence test [31] (see Methods section for the details).
The simplest method, the comparative ΔCt method,
uses only raw values of threshold cycles Ct. An application
of the ΔCt method to the results of RT-qPCR analysis of
39 breast cancer tissue samples for 18 genes from the set
for validation gave the following results (Figure 1a,
Additional file 6: Figure S1). Ten genes, namely, ACTB,
HUWE1, RPS23, EEF1A1, SF3A1, HCFC1, RPL37A,
MRPL19, TBP and TFRC showed nearly the same expres-
sion stability for the whole set of samples (Figure 1a). The
RPL23A gene displayed the lowest stability in the whole
set of samples and ER-negative tumors (Additional file 6:
Figure S1). The highest variability for ER- positive tumors
was exhibited by PSMC4.
In contrast to the comparative ΔCt method, geNorm,
NormFinder and Haller equivalence test use expression
levels as input data. The values of expression stability
MgeNorm for 18 candidate genes generated by the
most widely used algorithm geNorm are presented in
Figure 1b and Additional file 6: Figure S1. The 10
top-ranked genes were similar to the top-10 genes in the
rating generated by the comparative ΔCt method in the
whole set of samples: stability values of their expression
were nearly the same in each sample group and only the
exact order of genes was slightly different.
Unlike comparative ΔCt method and geNorm,
NormFinder and Haller equivalence test examine the ex-
pression stability of each candidate independently from












































































































































































































































































































































































































































Figure 1 Evaluation of candidate reference gene expression stability by RT-qPCR. Gene expression variations calculated for aggregated set
of samples by a: comparative ΔCt (MΔCt); b: geNorm (MgeNorm) and d: NormFinder (MNormFinder). c: Maximum fold changes of gene expression
levels MHaller calculated by Haller equivalence test.
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and Additional file 6: Figure S1. In intergroup variation
analysis groups were formed by ER-positive and ER-
negative samples, respectively (Additional file 7: Figure S2).
Higher stability was observed for ACTB, RPS23, HUWE1,
EEF1A1, MRPL19, SF3A1, HCFC1, RPL37A and TBP.
The Haller equivalence test allows to evaluate a fold
change value (MHaller) of candidate reference genes ex-
pression level between different samples for a given sig-
nificance value. The results of the expression variability
estimation for the 18 candidate genes studied are
presented in Figure 1c and Additional file 6: Figure S1.
In contrast to the comparative ΔCt method, geNorm
and NormFinder PSMC4 demonstrated the lowest vari-
ability for the whole set of samples as well as for ER-
negative and ER-positive tumors. The next gene in the
stability ranking was RPL39, the third gene was ACTB
that demonstrated lowest variation according to other
methods of stability evaluation that A large group of
genes from the validation set (GUSB, RPS23, MRPL19,
RPL37A, SF3A1, HUWE1, TBP) showed very similar
MHaller values and were the next in stability ranking. In
concordance with the results of the comparative ΔCt
method, geNorm and NormFinder, RPL23A had the
greatest expression variability. The relatively high MHaller
values of all candidate genes are consistent with highly
heterogeneous nature of biopsies and with other studies
[15,47]. Also it is worth noting that MHaller stabilityvalues are “pessimistic” in comparison with other
methods as they represent the “poor case”, but not the
“averaged” one (see details in Methods).
An important inference is that such genes as GAPDH
and RPLP0, commonly employed as reference genes
(e.g., in the commercial Oncotype DX diagnostic test)
were ranked among the most variable candidate genes
by almost all methods.
Final selection of reference genes
Thus four rankings of gene expression stability were
obtained by the following methods: comparative ΔCt
method [8], geNorm [12], NormFinder [1,30] and Haller
equivalence test [31]. In spite of the fact that generally
the results of all stability evaluation methods are consist-
ent each of these ranking has its own order of the genes.
Based on both four stability rankings and intergroup var-
iations calculated by NormFinder we formed a subset of
the best 5 reference genes: ACTB, RPS23, HUWE1,
EEF1A1, SF3A1 (other good choices can be obtained by
a replacement of EEF1A1 or SF3A1 by MRPL19). Note
that three out of five genes in this set (RPS23, HUWE1,
EEF1A1) were selected by microarray analysis and were
top-ranked in the extended list of candidate genes.
ACTB was not included in the extended list of candidate
genes only because it had high intergroup variation be-
tween normal epithelium samples from cancer and
cancer-free patients. However it showed low variability
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tion of the extended list.
In order to validate the selected subset of reference
genes we added a “quasi-gene” corresponding to the set
of 5selected genes (see Methods section for details) and
calculated the stability measures by all four methods
(Table 4). The results show that the selected subset
clearly outperforms not only every individual gene from
the tested set, but also a system of reference genes used
by OncotypeDX test. The only method that did not rank
the selected set as the most stable was the Haller equiva-
lence test: it ranked the individual gene PSMC4 higher
than “quasi-genes”.
Discussion
RT-qPCR has become the most popular method for
detection and quantification of mRNA transcripts. An
efficient normalization enables the gathering of reprodu-
cible and biologically relevant RT-qPCR data correcting
non-biological sample-to-sample variations that could be
introduced by protocol-dependent inconsistencies [1,30].
To achieve an efficient normalization the use of internal
control genes (reference genes) has been established as
the gold standard normalization method. Formerly, the
genes that have housekeeping roles in basal cellular
activities were selected as internal control for gene
expression studies. However, it is obvious now that a
housekeeping function does not guarantee that a gene
has a stable expression level. It was well documented
that expression levels of many commonly used house-
keeping genes, including GAPDH, ACTB, RPS18, UBC,
B2M, HPRT1 and others, may vary significantly in differ-
ent tissues and cells [4,7,9,11-15]. Therefore it is neces-
sary to identify novel candidate reference genes for given
individual studies.
Our goal was to select a set of reference genes that
can be efficiently used for both research and clinical ana-
lysis of breast cancer samples with an unknown hor-
mone receptor status and different cancer status. InTable 4 Stability characteristics evaluated for the system
of 18 individual genes and 2 “quasi-genes” – one
corresponding to the selected system of reference genes,
and the other corresponding to the system of reference
genes used in OcotypeDX test
Aggregate set of samples
ΔCt geNorm Haller Norm Finder
Best gene* ACTB ACTB PSMC4 ACTB
0.864 0.789 1.853 0.252
Selected subset 0.767 0.706 3.138 0.114
OncotypeDX subset 0.866 0.805 3.157 0.263
*Best gene corresponds to gene with the least variability characteristic among
18 genes.order to achieve this goal we developed the strategy for
the selection of reference genes that consists of the
following stages: 1) selection of an extended list of can-
didate reference genes based on microarray data, 2)
selection of a set of candidate genes for validation by
RT-qPCR and 3) selection of the final set.
Similarly to the studies presented in [14,24] we started
from the analysis of available microarray datasets, how-
ever, we used variation characteristics that are more
stable with respect to outliers. This analysis allowed us
to identify 25 genes with stable expression level for the
studied sample types (Table 3). Forming the list of candi-
date genes for validation, we took into account the pos-
sible interactions of genes and their involvement in the
same biological pathways. The final set of reference
genes was selected based on four stability rankings gen-
erated by the most widely used methods for evaluation
of gene expression variability. This allowed us to take
advantage of all considered methods. We noted that
both microarray and RT-qPCR data allows to evaluate
only the stability of a transcript portion of an individual
gene in a fixed amount of total RNA, or, in other words,
to evaluate the relative stability of gene expression.
Hence it is a natural idea to use tools that estimate the
expression stability of a gene relative to the expression
of other genes, e.g. the comparative ΔCt method [8] and
the geNorm [12]. However, low values of such relative
variation characteristics can be a result of gene co-
regulation. That is why the usage of tools based on sta-
bility measures of individual genes independently on
other genes such as NormFinder and Haller equivalence
test is very reasonable.
All methods used for the gene stability evaluation
showed that the genes selected by microarray analysis
are comparable with or even better than traditionally
used reference genes: in the final subset 3 out of 5 genes
belonged to the list of genes selected by means of micro-
array analysis. These three genes are RPS23, HUWE1
and EEF1A1.
Conclusions
We presented experimentally validated evidence that a
selection of reference genes for RT-qPCR can be effi-
ciently performed by combining a preliminary search
based on the high-throughput analysis of microarray
datasets with subsequent selection and validation using
RT-qPCR and simultaneous examination of different ex-
pression stability measures. We showed that the identi-
fied set of reference genes, including ACTB, RPS23,
HUWE1, EEF1A1 and SF3A1 proved to be less variable
and thus potentially more efficient for research and
clinical analysis of breast samples in comparison with
individual genes and a set of reference genes used in
OncotypeDX assay.
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